Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Cancer Surgery
Synchronous resection of the liver lung with metastases
Synchronous resection of the liver lung with metastases involves removing secondary cancer spread from both organs during a single operation or coordinated surgical plan. Typically considered for oligometastatic colorectal cancer, this complex procedure requires extensive multidisciplinary assessment. This guide explains patient suitability, combined versus staged surgical approaches, safety considerations, typical recovery trajectories, and treatment costs when travelling to Turkey.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Cancer Surgery
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Synchronous Resection of the Liver Lung with Metastases
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
What is synchronous resection of the liver lung with metastases?
Synchronous resection of the liver lung with metastases refers to the surgical removal of secondary cancer deposits from both hepatic tissue and pulmonary parenchyma during a single coordinated surgical procedure. When malignant cells spread beyond a primary site—most frequently seen in advanced colorectal malignancy—the liver and the lungs are the two most common destination organs. In historical practice, multi-organ metastatic spread was deemed incurable and managed solely with palliative chemotherapy. Modern oncological surgery, supported by high-resolution cross-sectional imaging and refined parenchymal-sparing techniques, now allows surgeons to excise metastases from both organs with curative intent.
The primary mechanism of this intervention relies on achieving clear microscopic margins, medically termed an R0 resection, while preserving sufficient functional reserve in both the liver and lungs. Synchronous spread to both the hepatic parenchyma and pulmonary tissue most commonly arises in advanced colorectal malignancy; patients frequently undergo primary tumour management such as removal of colon cancer alongside or prior to metastatic resection. By eliminating all macroscopic deposits simultaneously, the surgical team halts metastatic progression, prevents local organ failure, and creates a favourable baseline for subsequent systemic treatments.
Does surgical resection of liver and lung metastases improve survival?
Clinical evidence gathered over the last two decades demonstrates that aggressive surgical resection of oligometastatic cancer—disease confined to a limited number of treatable lesions—substantially improves overall survival compared to systemic therapy alone. Hepatobiliary and thoracic surgical consensus guidelines, including recommendations from the European Society for Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN), recognise dual-organ metastasectomy as a valid therapeutic pathway for appropriately selected patients.
Long-term observational studies and multicentre registry analyses report five-year overall survival rates ranging between 30% and 50% following complete resection of synchronous liver and lung lesions originating from colorectal primaries. In contrast, historical five-year survival under chemotherapy alone rarely exceeded 10% to 15%. However, the evidence also underscores important caveats: recurrence occurs in roughly 50% to 60% of patients within two to three years. Surgery does not eliminate microscopic circulating tumour cells, meaning it works most effectively as part of a multimodal regimen combining neoadjuvant and adjuvant systemic therapies to control micro-metastatic disease.
Candidate selection: who is suitable for simultaneous liver and lung surgery?
Simultaneous multi-organ metastasectomy imposes considerable physiological stress, making rigorous patient selection paramount. A dedicated multidisciplinary tumour board (MDT) evaluates each case based on anatomical resectability, baseline organ reserve, and individual performance status. Unlike isolated breast procedures like a lumpectomy, managing dual-organ secondary disease demands coordinated input from colorectal, thoracic, and hepatobiliary surgeons.
Favourable candidates typically present with:
- Controlled or resectable primary tumour site with no evidence of uncontrolled local recurrence.
- Limited number of metastatic lesions, typically one to four liver lesions and one to two unilateral lung nodules.
- Adequate future liver remnant (FLR), generally requiring at least 25% to 30% healthy functional tissue in normal livers, or 40% in chemotherapy-injured parenchyma.
- Sufficient baseline pulmonary function, confirmed via spirometry and carbon monoxide diffusion capacity tests.
- Good performance status (ECOG 0 or 1) indicating adequate cardiac and systemic fitness to tolerate extensive surgery.
Conversely, contraindications include unresectable extrahepatic and extrapulmonary metastases (such as extensive peritoneal carcinomatosis or bone metastases), severe portal hypertension, inadequate respiratory reserve that would risk post-operative ventilator dependence, and severe uncorrected cardiac disease.
Surgical techniques: how simultaneous liver and lung metastasectomy is performed
The execution of simultaneous liver and lung surgery involves coordinated operative phases conducted under general anaesthesia with specialized double-lumen endotracheal intubation, allowing selective one-lung ventilation. The surgical team typically comprises two dedicated units: a hepatobiliary surgical team and a thoracic surgical team. Total operative duration usually ranges from four to eight hours depending on lesion depth and technical complexity.
Surgical access strategies vary according to the exact location of the lesions. When pulmonary metastases reside in the right lower lobe and liver lesions are in the upper cranial segments (such as segments VII and VIII), surgeons may occasionally utilise a combined thoracoabdominal incision or a right subcostal laparotomy paired with transdiaphragmatic access. More commonly, dual independent access is selected: a right subcostal or midline laparotomy (or laparoscopic liver resection) followed immediately by video-assisted thoracic surgery (VATS) or a muscle-sparing thoracotomy. Liver resection prioritises parenchymal-sparing non-anatomical wedge excisions or anatomical segmentectomies using intraoperative ultrasound guidance. For pulmonary nodules, sublobar wedge resection is the standard preference to conserve healthy respiratory volume, reserving anatomical lobectomy for deeply situated central lesions.
Simultaneous versus staged resection: comparing surgical strategies
When patients present with synchronous metastases in both organs, surgical oncologists evaluate whether to perform a simultaneous intervention or a staged sequential approach. In a staged strategy, the liver is commonly resected first due to the higher risk of hepatic progression, followed six to twelve weeks later by thoracic surgery, or vice versa if pulmonary lesions threaten the major airway.
Each strategy offers distinct clinical trade-offs regarding operative stress, total recovery timeline, and oncological security. The following table contrasts simultaneous resection with sequential staged approaches and non-surgical local ablative alternatives.
| Approach | Method Overview | Appropriate Clinical Setting | Typical Limitations |
|---|---|---|---|
| Synchronous Resection | Single-session combined abdominal laparotomy or laparoscopy and thoracic resection (VATS or thoracotomy). | Unilateral lung lesions, limited accessible liver metastases, robust cardiopulmonary reserve. | High acute physiological stress, prolonged single anaesthetic, limited to unilateral thoracic access. |
| Staged Resection | Two separate surgical sessions spaced 6 to 12 weeks apart (liver-first or lung-first sequence). | Bilateral pulmonary metastases, complex major hepatectomies, marginal initial physical fitness. | Requires two hospitalisations, prolonged overall recovery, risk of interval progression during waiting periods. |
| Local Ablation (RFA / SBRT) | Radiofrequency ablation, microwave ablation, or stereotactic body radiotherapy without surgical excision. | Patients medically unfit for major surgery, deeply placed lesions under 3 cm unsuitable for resection. | Higher local recurrence rate than surgical margins, absence of tissue histology, size limitations. |
What is the synchronous resection of the liver lung with metastases cost?
Understanding the synchronous resection of the liver lung with metastases cost requires assessing the extensive hospital infrastructure demanded by dual-organ surgery. Because the operation involves two surgical teams, advanced intraoperative imaging, prolonged operating theatre utilisation, and compulsory post-operative intensive care, prices are substantially higher than single-organ interventions. Factors influencing the total synchronous resection of the liver lung with metastases price include the anatomical extent of resection (wedge versus lobectomy or major hepatectomy), length of ICU stay, requirement for advanced blood-salvage technologies, and post-operative pharmaceutical needs.
Many international patients travel abroad to access specialised surgical teams without prohibitive waiting lists or excessive out-of-pocket expenses. Many international facilities providing oncology treatments in Turkey offer consolidated packages encompassing surgical fees, intensive care stays, and post-operative pathology. Understanding how it works when arranging complex overseas medical travel helps patients navigate logistical preparation and surgical quotes.
| Country | Approximate Cost Range (€) | Typical Inpatient Stay | Key Package Components |
|---|---|---|---|
| Turkey | €18,000 – €35,000 | 7 – 14 days | Dual surgeon teams, pre-op scans, ICU care, nursing, pathology review, airport transfers. |
| United Kingdom | €32,000 – €65,000 | 7 – 14 days | Hospital bed fees, theatre time, consultant surgeon and anaesthetist fees; excludes pre-op workup. |
| Germany | €30,000 – €58,000 | 8 – 15 days | DRG hospital billing, dual surgical team fees, high-dependency care, acute rehabilitation. |
| United States | €75,000 – €160,000 | 7 – 12 days | Itemised facility charges, separate surgeon and anaesthesia bills, medication and ICU surcharges. |
When evaluating synchronous resection of the liver lung with metastases in Turkey, patients should ensure that quotes clearly define the included number of intensive care unit days, as unexpected prolonged ICU support can alter final invoices in unbundled pricing models.
Recovery milestones: what to expect after dual-organ surgery
Navigating synchronous resection of the liver lung with metastases recovery requires careful patience, as healing occurs simultaneously in both the thoracic and abdominal cavities. Immediately following the operation, patients are transferred to the intensive care unit (ICU) or high-dependency unit (HDU) for continuous cardiovascular, pulmonary, and hepatic function monitoring. Chest drains remain in place to evacuate pleural fluid and air, while abdominal drains monitor for bile leaks or bleeding.
The typical post-operative trajectory follows predictable stages:
- Days 1 to 3 (ICU/HDU): Pain management via epidural or patient-controlled analgesia; early bedside sitting; respiratory physiotherapy with incentive spirometry to prevent atelectasis.
- Days 4 to 7 (Surgical Ward): Removal of urinary catheter and thoracic chest drains once drainage volume decreases and air leaks resolve; gradual transition to solid oral nutrition and assisted corridor walking.
- Days 8 to 14 (Discharge & Local Convalescence): Removal of abdominal drains; discharge to local hotel accommodation near the clinic; continuing oral analgesics and daily mobility walks.
- Weeks 3 to 6: Substantial recovery of energy; wound healing review; progressive return to light daily tasks while avoiding lifting anything heavier than 5 kg.
- Weeks 6 to 12: Final surgical wound consolidation; restaging imaging; clearance to resume systematic physical exercise or initiate adjuvant systemic chemotherapy.
International patients must plan to remain near the treating hospital for a minimum of 18 to 25 days before receiving formal medical clearance for international flights.
Complications and clinical risks of combined abdominal and thoracic surgery
Undergoing simultaneous major surgery across two anatomical compartments introduces distinct clinical risks. While advanced surgical centres report thirty-day post-operative mortality rates below 3% to 5%, overall morbidity remains notable due to the additive effects of laparotomy and thoracotomy.
Potential complications documented in surgical literature include:
- Pulmonary complications: Pneumonia, persistent air leaks lasting longer than five days, pleural effusions, and atelectasis, which represent the most common post-operative challenges.
- Hepatic complications: Transient liver dysfunction, post-resection hemorrhage, and bile leaks from the cut liver surface occurring in 3% to 8% of cases.
- Infections: Surgical site infections, intra-abdominal abscesses, or chest cavity empyema requiring antibiotic therapy or percutaneous drainage.
- Thromboembolism: Deep vein thrombosis (DVT) and pulmonary embolism (PE), managed through mechanical compression stockings and prophylactic low-molecular-weight heparin.
- Diaphragmatic hernia: Occurs rarely if surgical access involved transdiaphragmatic incisions that fail to heal securely under respiratory motion.
Surgeons mitigate these risks by conducting meticulous pre-operative respiratory evaluations, using intraoperative blood-sparing techniques, and enforcing aggressive post-operative chest physiotherapy.
Evaluating surgical outcomes: post-operative imaging and surveillance
In oncology, post-operative assessments are not evaluated through aesthetic changes, but through high-precision cross-sectional radiology and biochemical tumour markers. Before surgery, contrast-enhanced CT, liver-specific MRI, and 18F-FDG PET-CT scans map the exact coordinates, sizes, and metabolic activity of all hepatic and pulmonary nodules. These images establish baseline measurements and guide surgical resection margins.
Post-operative surveillance imaging, performed at baseline 4 to 8 weeks post-surgery and repeated every 3 to 6 months thereafter, serves to confirm complete microscopic clearance (R0). Follow-up scans reveal anatomical remodelling, surgical clip artefacts, and harmless post-surgical scar tissue. What imaging cannot show are microscopic cellular clusters, which is why serum tumour markers—such as carcinoembryonic antigen (CEA) in colorectal cases—are tracked closely alongside imaging. If recurrence is detected early during surveillance, up to 30% of patients remain eligible for repeat targeted intervention.
Selecting an oncology surgical team and essential questions to ask
Undergoing synchronous resection of the liver lung with metastases Turkey requires meticulous hospital selection. Patients should never entrust dual-organ metastatic surgery to general surgical clinics. The chosen centre must function as a comprehensive tertiary hospital equipped with accredited surgical oncology, hepatobiliary, and thoracic departments, alongside on-site interventional radiology and dedicated surgical intensive care.
Patients exploring comprehensive staging following their initial removal of colon cancer should verify that their overseas hospital hosts regular multidisciplinary tumour board reviews. Before committing to treatment, patients should discuss the following questions directly with their surgical team:
- Does an institutional multidisciplinary tumour board review my imaging and pathology before surgery?
- How many combined or staged liver and lung metastasectomies do your hepatobiliary and thoracic teams perform annually?
- What is your centre's 30-day complication rate and intensive care duration for simultaneous resections?
- Will the liver and lung resections be performed by two separate sub-specialist surgeons or a single surgical team?
- What is the emergency protocol if I develop a persistent air leak or bile leak after discharge from the hospital?
- What specific criteria will you use to determine my fitness to fly back home?
To review candidate eligibility and receive an itemised surgical estimate, patients can submit their recent CT and PET-CT scans for a free quote.
Hospitals with Oncology in Turkey
Frequently asked questions
Synchronous resection of the liver lung with metastases is a complex surgical procedure where secondary cancer deposits in both the liver and the lung are excised during the same operative session. It aims to achieve complete tumour clearance (R0 resection) in carefully selected patients whose primary cancer, often colorectal, has spread oligometastatically to both organs.
Surgery alone is not considered a definitive cure, but complete surgical resection provides the most reliable pathway toward long-term disease-free survival in oligometastatic disease. Published oncological registry data indicate five-year overall survival rates between 30% and 50% for selected candidates, compared to significantly lower rates achievable through systemic palliative chemotherapy alone.
In Turkey, combined liver and lung metastasectomy typically ranges from approximately €18,000 to €35,000, covering pre-operative planning, bilateral surgical teams, anaesthesia, and inpatient intensive care. Comparable private treatment in the UK or Germany ranges from €30,000 to €65,000, while in the United States costs frequently exceed €75,000 depending on hospital stay duration.
Pre-operative CT and PET scans show active hypermetabolic nodules within the hepatic parenchyma and pulmonary lobes. Post-operative surveillance imaging typically displays anatomical post-resection changes, surgical clips, and non-enhancing scar tissue, confirming the absence of residual macroscopic tumour. Scans are repeated every three to six months to monitor for potential local or distant recurrence.
Initial hospitalisation lasts 7 to 14 days, including mandatory monitoring in the intensive care unit. Light domestic mobility generally resumes by weeks 3 to 4, but full functional recovery and return to standard physical activity usually takes 8 to 12 weeks. Systemic adjuvant chemotherapy, if planned, commonly resumes around week 6 to 8.
Because the operation involves both abdominal incisions and thoracic access, post-operative discomfort can be significant without tailored analgesia. Surgical teams manage pain through thoracic epidural catheters, patient-controlled intravenous analgesia, and regional nerve blocks. Discomfort is most intense during the initial 72 hours and gradually subsides to manageable soreness over several weeks.
When complete microscopic clearance (R0) is achieved, patients may achieve disease-free survival spanning many years. While roughly half of all patients develop recurrent metastatic lesions within two to three years, many remain candidates for further targeted local therapy, repeat resection, or maintenance systemic immunotherapy and chemotherapy.
The operation carries measurable surgical risks given the physiological stress of operating on two major organ systems simultaneously. However, in specialised centres with dedicated hepatobiliary and thoracic surgical teams, thirty-day post-operative mortality is generally reported below 3% to 5%. Rigorous pre-operative assessment of cardiopulmonary reserve and functional liver volume is essential to ensure safety.
Synchronous resection eliminates all macroscopic disease in one hospitalisation, sparing the patient a second major operation and avoiding treatment delays. Conversely, staged resection separates abdominal and thoracic interventions by several weeks, reducing acute physiological stress and permitting assessment of tumour biology between stages. The choice depends on tumour burden, anatomical location, and overall patient fitness.
Patients should plan for a total stay of 18 to 25 days in Turkey. This window includes 2 to 3 days of pre-operative cross-sectional imaging and multidisciplinary review, 7 to 14 days of inpatient hospital care, and 7 to 10 days of post-discharge local convalescence before a final fitness-to-fly clearance.
Patient stories